Dublin and London-listed pharmaceutical services company Hvivo delivered record revenues and grew its profit to almost £4 million (€4.6 million) in the first six months of this year, its interim results show.
The company, formerly known as Open Orphan, described the first half of 2023 as “another period of excellent growth”. Its profit of more than £3.9 million for the period was up from £277,000 in the same period of 2022 and a loss of £776,000 in the second half of last year.
The company, which specialises in testing infectious and respiratory disease products, delivered record revenue of £27.3 million, which represented a 52 per cent increase on the £18 million delivered the previous year.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
